Global Network Point-of-Care Glucose Testing Market Share, Size, Trends, Industry Analysis Report, By Product (Accu-Chek Inform II, StatStrip, HemoCue, BAROzen H Expert Plus, i-STAT, CareSens Expert Plus); By Region; Segment Forecast, 2023 - 2032

The Global Network Point-of-Care Glucose Testing market was valued at USD 1,571.63 million in 2022 and is expected to grow at a CAGR of 3.8% during the forecast period. Network point-of-care glucose testing (NPoCT) refers to using networked glucometers to test blood glucose levels in patients at the point of care, typically in a clinical or hospital setting. This approach offers several advantages over traditional laboratory-based glucose testing, including reduced turnaround times, improved patient care, and increased cost-effectiveness. NPoCT systems typically comprise a networked group of glucometers that transmit test results to a central database for analysis and management. The systems are designed to provide healthcare providers with real-time glucose level information, allowing for rapid and informed treatment decisions.

To Understand More About this Research: Request a Free Sample Report

NPoCT systems have become increasingly common in recent years due to the growing demand for faster, more efficient, and more accurate testing methods. The designs are particularly useful in the management of diabetes, a chronic disease that affects millions of people worldwide. NPoCT systems allow healthcare providers to monitor glucose levels in diabetic patients more frequently, which can lead to better glycemic control and a reduced risk of complications. Additionally, the systems can monitor glucose levels in hospitalized patients, where frequent testing is often necessary to prevent hypoglycemia or hyperglycemia.

Network Point-of-Care Glucose Testing Market systems offer several advantages for healthcare providers. For one, the systems can reduce the overall cost of care by reducing the need for expensive laboratory testing and decreasing the length of hospital stays. Additionally, the systems can improve patient satisfaction and outcomes by providing real-time information that allows healthcare providers to make informed treatment decisions. This, in turn, can lead to better patient outcomes and increased patient loyalty.

Despite the many advantages of NPoCT systems, several challenges must be addressed. For example, the systems must be designed and implemented to ensure data security and patient privacy. Additionally, the systems must be integrated into existing healthcare IT systems, which can be complex and time-consuming. Finally, the methods must be easy to use and maintain, as healthcare providers may need more time or expertise to manage complex IT systems.

Network point-of-care glucose testing offers many advantages for healthcare providers and patients alike. By providing real-time glucose level information, NPoCT systems can help to improve patient outcomes, reduce healthcare costs, and increase patient satisfaction. However, successfully implementing NPoCT systems requires careful planning, robust data security measures, and effective integration with healthcare IT systems. With proper planning and execution, NPoCT systems have the potential to revolutionize the management of diabetes and other chronic diseases, improving the lives of millions of people worldwide.

Industry Dynamics

Growth Drivers

Network point-of-care glucose testing (NPoCT) is a rapidly growing healthcare industry segment driven by technological advances, changing patient needs, and an increasing focus on cost-effectiveness and efficiency. NPoCT involves using networked glucometers to test blood glucose levels at the point of care, typically in a clinical or hospital setting. NPoCT systems have become increasingly common in recent years due to several growth drivers.

One of the primary growth drivers for NPoCT is the increasing prevalence of diabetes, a chronic disease affecting millions worldwide. Frequent and accurate glucose monitoring is critical in managing diabetes, and NPoCT systems offer a more efficient and cost-effective alternative to traditional laboratory-based testing methods. NPoCT systems allow healthcare providers to monitor glucose levels more frequently, leading to better glycemic control and improved patient outcomes.

The growth driver for NPoCT is the increasing demand for point-of-care testing in general. Point-of-care testing allows healthcare providers to quickly and accurately diagnose and treat patients, leading to improved patient outcomes and reduced healthcare costs. NPoCT systems offer many of the same advantages, providing real-time glucose level information that allows for rapid and informed treatment decisions.

Advances in technology are also driving the growth of NPoCT. The development of networked glucometers, wireless communication, and cloud-based data management systems has made it easier and more cost-effective to implement NPoCT systems. These technological advances have also led to improved glucose testing accuracy and reliability, further enhancing NPoCT systems' utility in clinical settings.

The growth of NPoCT represents a significant opportunity for healthcare providers and medical device companies. NPoCT systems offer healthcare providers a way to improve patient outcomes while reducing healthcare costs and increasing efficiency and profitability. For medical device companies, the growing demand for NPoCT systems presents an opportunity to develop and market innovative products that meet the needs of healthcare providers and patients.

Network point-of-care glucose testing is a rapidly growing segment of the healthcare industry, driven by technological advances, changing patient needs, and an increasing focus on cost-effectiveness and efficiency. NPoCT systems offer healthcare providers a way to improve patient outcomes while reducing healthcare costs, leading to increased efficiency and profitability. With continued investment in research and development, NPoCT systems have the potential to revolutionize the management of diabetes and other chronic diseases, improving the lives of millions of people worldwide.

Report Segmentation

The market is primarily segmented based on product, and region

To Understand the Scope of this Report: Speak to Analyst

The I-Stat Segment is Expected to Witness the Fastest Growth During Forecast Period

The i-STAT segment is one of the fastest-growing segments in the point-of-care testing (POCT) market. The i-STAT system is a handheld device that provides real-time blood analysis and delivers results within minutes. The system is widely used in emergency departments, critical care settings, and other point-of-care settings.

The i-STAT system offers several advantages over traditional laboratory-based testing methods. First, it allows for rapid and accurate testing, leading to faster diagnosis and treatment decisions. Second, the system is portable and can be used in a variety of settings, including ambulances, emergency rooms, and physicians' offices. Finally, the i-STAT system offers a range of tests, including blood gases, electrolytes, and cardiac markers, making it a versatile tool for healthcare providers.

The growth of the i-STAT segment is driven by several factors. First, the increasing prevalence of chronic diseases, such as diabetes and heart disease, has led to a growing demand for point-of-care testing systems. Second, the i-STAT system is well-suited for use in emergency and critical care settings, where rapid and accurate diagnosis is critical. Third, the i-STAT system offers a range of tests, making it a versatile tool for healthcare providers.

Another factor driving the growth of the i-STAT segment is the increasing focus on cost-effectiveness and efficiency in healthcare. The i-STAT system is a cost-effective alternative to traditional laboratory-based testing methods, as it reduces the need for expensive equipment and trained personnel. Additionally, the system allows for rapid testing, reducing the time patients spend in emergency departments and other clinical settings.

The Accu-Chek Inform II Segment is Expected to Witness Largest Market Share During Projected Period

The Accu-Chek Inform II segment is expected to witness the largest market share in the point-of-care testing (POCT) market. The Accu-Chek Inform II system is a blood glucose monitoring device that provides rapid and accurate glucose testing in point-of-care settings. The system is widely used in hospitals, clinics, and physician offices for the management of diabetes.

The Accu-Chek Inform II system offers several advantages over traditional laboratory-based testing methods. First, it provides rapid and accurate glucose testing, allowing healthcare providers to make informed treatment decisions. Second, the system is portable and can be used in a variety of point-of-care settings, making it a versatile tool for healthcare providers. Finally, the system offers a range of connectivity options, including wireless and Ethernet, allowing for easy data management and sharing.

The growth of the Accu-Chek Inform II segment is driven by several factors. First, the increasing prevalence of diabetes worldwide has led to a growing demand for point-of-care testing systems. Second, the Accu-Chek Inform II system is well-suited for use in hospitals and clinics, where frequent and accurate glucose monitoring is critical for the management of diabetes. Third, the system offers a range of connectivity options, making it easy for healthcare providers to manage patient data and share information with other healthcare providers.

The Demand in North America Region is Expected to Witness Significant Growth

The demand for point-of-care testing (POCT) systems is expected to witness significant growth in North America in the coming years. North America is a mature and well-established healthcare market with a high burden of chronic diseases and a growing focus on value-based care.

The increasing prevalence of chronic diseases, such as diabetes, cardiovascular disease, and cancer, is a key driver of the demand for POCT systems in North America. These conditions are associated with a high economic and social burden and require frequent and accurate monitoring. POCT systems can provide rapid and accurate diagnostic tools in a variety of healthcare settings, helping to improve patient outcomes and reduce healthcare costs.

Another factor driving the demand for POCT systems in North America is the increasing focus on value-based care. Value-based care emphasizes the delivery of high-quality care that is both effective and efficient. POCT systems can help healthcare providers achieve these goals by providing rapid and accurate diagnostic tools that can lead to improved patient outcomes and reduced healthcare costs.

The increasing adoption of healthcare technologies, such as telemedicine and remote monitoring, is expected to drive the demand for POCT systems in North America. These technologies are transforming the way healthcare is delivered in the region and are creating new opportunities for point-of-care testing.

Competitive Insight

Some of the major key player of the market includes F. Hoffmann-La Roche Ltd., Bayer AG/Ascensia Diabetes Care Holdings AG, Nova Biomedical, Abbott, LLC (Lifescan, Inc.), and Danaher.

Recent Developments

In March 2021, EKF Diagnostics, an in vitro diagnostics company, has globally launched STAT-Site WB handheld analyzer that provides glucose and β-ketone in blood taken from capillary or venous samples.

Network Point-of-Care Glucose Testing Market Report Scope